Products Categories
| CAS No.: | 7232-21-5 |
|---|---|
| Name: | METOCLOPRAMIDE HCL |
| Molecular Structure: | |
|
|
|
| Formula: | C14H22ClN3O2.HCl |
| Molecular Weight: | 336.262 |
| Synonyms: | Benzamide,4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI);o-Anisamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-, monohydrochloride(8CI);4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-o-anisamide hydrochloride;AHR 3070-C;Ami-metoclopramide;Cerucal;Maxolon;Metoclopramide monohydrochloride;Metoclopramide-Hakim;Metpamid;Mexeron;NSC354467;Paspertin;Perinorm;Plazilin;Primperan (tablet);Reglan;Rimetin;Telperane;Tserulan; |
| EINECS: | 206-662-9 |
| Melting Point: | 171-173 °C |
| Boiling Point: | 418.7 °C at 760 mmHg |
| Flash Point: | 207 °C |
| Solubility: | souble in water |
| Appearance: | white solid |
| Hazard Symbols: |
 Xn
|
| Risk Codes: | 22 |
| Safety: | 26-36 |
| PSA: | 67.59000 |
| LogP: | 3.77650 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- 90221-55-92-bromo-5-methylbenzaldehyde
- 885590-99-82,3-DIFLUORO-4-IODOBENZALDEHYDE
What can I do for you?
Get Best Price
Specification
The IUPAC name of Metoclopramide hydrochloride is 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide hydrochloride. With the CAS registry number 7232-21-5, it is also named as Benzamide,4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-, hydrochloride (1:1). The product's categories are antagonists, dopaminergics, neurotransmitters and dopamine receptor and the other registry number is 49625-23-2. Moreover, it is white solid and souble in water, its molecular formula is C14H23Cl2N3O2, and molecular weight is 336.26.
The other characteristics of Metoclopramide hydrochloride can be summarized as: (1)EINECS: 230-634-5; (2)ACD/LogP: 2.22; (3)# of Rule of 5 Violations: 0; (4)ACD/LogD (pH 5.5): -0.85; (5)ACD/LogD (pH 7.4): 0.04; (6)ACD/BCF (pH 5.5): 1; (7)ACD/BCF (pH 7.4): 1; (8)ACD/KOC (pH 5.5): 1; (9)ACD/KOC (pH 7.4): 2.54; (10)H bond acceptors: 5; (11)H bond donors: 3; (12)Freely Rotating Bonds: 8; (13)Rotatable Bond Count: 7; (14)Tautomer Count: 5; (15)Exact Mass: 335.116732; (16)MonoIsotopic Mass: 335.116732; (17)Heavy Atom Count: 21; (18)Complexity: 300; (19)Polar Surface Area: 36.02 Å2; (20)Flash Point: 207 °C; (21)Enthalpy of Vaporization: 67.23 kJ/mol; (22)Boiling Point: 418.7 °C at 760 mmHg; (23)Vapour Pressure: 3.22E-07 mmHg at 25 °C.
When you are using this chemical, please be cautious about it as the following: Metoclopramide hydrochloride is harmful if swallowed. So when you use it, please wear suitable protective clothing. Besides, in case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
People can use the following data to convert to the molecule structure.
(1)SMILES:Clc1cc(c(OC)cc1N)C(=O)NCCN(CC)CC.Cl
(2)InChI:InChI=1/C14H22ClN3O2.ClH/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3;/h8-9H,4-7,16H2,1-3H3,(H,17,19);1H
(3)InChIKey:RVFUNJWWXKCWNS-UHFFFAOYAU
(4)Std. InChI:InChI=1S/C14H22ClN3O2.ClH/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3;/h8-9H,4-7,16H2,1-3H3,(H,17,19);1H
(5)Std. InChIKey:RVFUNJWWXKCWNS-UHFFFAOYSA-N
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| man | TDLo | intravenous | 143ug/kg (0.143mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) | Intensive Care Medicine. Vol. 12, Pg. 378, 1986. |
| man | TDLo | multiple routes | 85mg/kg/48W-I (85mg/kg) | BEHAVIORAL: ATAXIA | New England Journal of Medicine. Vol. 315, Pg. 518, 1986. |
| man | TDLo | oral | 400ug/kg/16H- (0.4mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: TREMOR BEHAVIORAL: REGIDITY | Anesthesia and Analgesia Vol. 66, Pg. 274, 1987. |
| man | TDLo | oral | 1mg/kg/2D-I (1mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | British Journal of Clinical Practice. Vol. 28, Pg. 201, 1974. |
| man | TDLo | oral | 1714ug/kg (1.714mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: REGIDITY | Southern Medical Journal. Vol. 81, Pg. 674, 1988. |
| man | TDLo | oral | 1161mg/kg/2D- (1161mg/kg) | BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Southern Medical Journal. Vol. 76, Pg. 817, 1983. |
| rat | LD50 | subcutaneous | 475mg/kg (475mg/kg) | Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971. | |
| women | TDLo | intravenous | 15mg/kg/9H-I (15mg/kg) | Clinical Pharmacy. Vol. 5, Pg. 342, 1986. | |
| women | TDLo | oral | 2400ug/kg/3D- (2.4mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: REGIDITY BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | Canadian Medical Association Journal. Vol. 126, Pg. 23, 1982. |